Boehringer Ingelheim GmbH didn’t disclose a data analysis to U.S. regulators that indicated the blood-thinner Pradaxa may have caused more fatal bleeding after it was cleared for sale than the drug did in a study used to win approval, unsealed court filings show.
Carl Icahn, the shareholder activist who waged two proxy fights for board seats at Forest Laboratories Inc., stands to earn almost $1.7 billion in gross profits on his 11 percent stake in the drug company.
Pharmaceutical companies from Merck & Co. to Bristol-Myers Squibb Co. face fresh threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs for local makers to copy.
Perrigo Co., the largest maker of generic over-the-counter medicines in the U.S., climbed to a record on prospects the company will push for more acquisitions after the purchase of Elan Corp. reduced its tax rate.
Teva Pharmaceutical Industries Ltd. chose board member Erez Vigodman to run the world’s biggest generic-drug maker, seeking to revive earnings growth and the stock after the previous CEO left in a dispute with the board.